Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib DDI with Rosuvastatin and Midazolam
NCT02082665Phase 1Completed
- Sponsor
- GSK
- Start
- Feb 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of dabrafenib + trametinib in solid tumor, sponsored by GSK. Primary endpoint: Pharmacokinetics (PK) parameter of rosuvastatin and midazolam at Day 22. Started Feb 2015; status: completed.
02
Drugs
dabrafenib + trametinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02082665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02082665.